Copyright
©2014 Baishideng Publishing Group Co.
World J Respirol. Mar 28, 2014; 4(1): 1-7
Published online Mar 28, 2014. doi: 10.5320/wjr.v4.i1.1
Published online Mar 28, 2014. doi: 10.5320/wjr.v4.i1.1
Table 2 Drug delivery n (%)
| Number of cycles delivered | |
| 1 | 61 (100) |
| 2 | 58 (95) |
| 3 | 51 (84) |
| Total | 170 |
| Median | 3 |
| Number of patients who required dose reduction of | |
| CBDCA | 43 (70) |
| DTX | 43 (70) |
| Mean dose intensity (% planned) | |
| CBDCA | 4.3 AUC (86.7) |
| DTX | 51.8 mg/m2 (86.3) |
| Median dose intensity (% planned) | |
| CBDCA | 4.3 AUC (86.7) |
| DTX | 53.3 mg/m2 (88.8) |
- Citation: Uramoto H, Nakanishi R, Uchiyama A, Inoue M, Sugaya M, Iwata T, Ebi N, Hanagiri T, Tanaka F. Phase II trial of carboplatin/docetaxel in patients with resected NSCLC. World J Respirol 2014; 4(1): 1-7
- URL: https://www.wjgnet.com/2218-6255/full/v4/i1/1.htm
- DOI: https://dx.doi.org/10.5320/wjr.v4.i1.1